Retatrutide appears to be a new pharmaceutical in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By activating these receptors, Retatrutide suppresses appetite, {promotesenergy expenditure, tirzepadine supplier and ultimately contributes to significant